D0657 | 24r,25-dihydroxyvitamin d3
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 13.02±2.17 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 15.45 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 17.34±0.00 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H301+H311 (100%): Toxic if swallowed or in contact with skin [Danger Acute toxicity, oral acute toxicity, dermal] H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral] H311 (100%): Toxic in contact with skin [Danger Acute toxicity, dermal] H330 (100%): Fatal if inhaled [Danger Acute toxicity, inhalation] H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P260, P264, P270, P271, P280, P284, P301+P310, P302+P352, P304+P340, P310, P312, P314, P320, P321, P322, P330, P361, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (24R),25-Dihydroxyvitamin D3 | (24R)-24,25-Dihydroxyvitamin D3, >=98% (vitamin + pre-vitamin, HPLC) | (24R)-24,25-dihydroxycalciol |
| (24R)-24,25-dihydroxycholecalciferol | (24R)-24,25-dihydroxyvitamin D3 | (24R)-24,25-dihydroxyvitamin D3 / (24R)-24,25-dihydroxycholecalciferol |
| (24R)-Hydroxycalcidiol | (3-beta,5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol | (3R,6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylene-cyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methyl-heptane-2,3-diol; |
| (3S,5Z,7E,24R)-9,10-secocholesta-5,7,10-triene-3,24,25-triol | (5Z,7E)-(3S,24R)-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol | (5Z,7E,24R)-9,10-Secocholesta-5,7,10(19)-triene-3beta,24,25-triol |
| 24(R),25-Dihydroxycholecalciferol | 24(R),25-Dihydroxyvitamin D3 | 24,25-Dihydroxycholecalciferol |
| 24,25-dihydroxyvitamin D3 | 24R,25(OH)2D3 | 24R,25-Dihydroxyvitamin D3 |
| 24R,25-Dihydroxyvitamin D3 (Secalciferol) | 24r,25-Dihydroxycholecalciferol | 40013-87-4 |
| 460029IUDA | 55721-11-4 | 9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol, (3beta,5Z,7E,24R)- |
| 9,10-Secocholesta-5,7,10-triene-3,24,25-triol, (3S,5Z,7E,24R)- | BML2-E04 | BSPBio_001409 |
| C07712 | CAS-55721-11-4 | CCRIS 8678 |
| CHEBI:108603 | CHEBI:28818 | CHEMBL1590076 |
| CS-0929 | D00628 | DSSTox_CID_1260 |
| DSSTox_GSID_21260 | DSSTox_RID_76045 | DTXSID4021260 |
| FCKJYANJHNLEEP-XRWYNYHCSA-N | HMS1361G11 | HMS1791G11 |
| HMS1989G11 | HMS3402G11 | HY-32343 |
| IDI1_033879 | K-DR | LMST03020273 |
| NCGC00161328-01 | NCGC00161328-03 | Osteo D |
| Osteo D (TN) | Q27103914 | Ro 21-5816 |
| SCHEMBL3597 | SECALCIFEROL | Secalciferol (JAN/USAN/INN) |
| Secalciferol [USAN:INN:BAN] | Secalciferolum | Secalciferolum [INN-Latin] |
| Tox21_111989 | UNII-0AXX2V8L5Z component FCKJYANJHNLEEP-XRWYNYHCSA-N | UNII-460029IUDA |
| V1825 | W-5235 | ZINC100051969 |